Parecoxib Enhances Resveratrol against Human Colorectal Cancer Cells through Akt and TXNDC5 Inhibition and MAPK Regulation
Nutrients · 2024
DOI: 10.3390/nu16173020 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nutrients, 2024. Verfasst von Wan-Ling Chang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, Chang Gung Memorial Hospital at Chiayi, No. 8, West Section of Jiapu Road, Chiayi County, Puzi City 613016, Taiwan. Hauptthemen laut MEDLINE: Resveratrol, Colorectal Neoplasms, Proto-Oncogene Proteins c-akt, Isoxazoles. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chiayi Chang Gung Memorial Hospital, Chang Gung Medical Foundation.
Abstract (Originalsprache)
In this study, we discovered the mechanisms underlying parecoxib and resveratrol combination’s anti-cancer characteristics against human colorectal cancer DLD-1 cells. We studied its anti-proliferation and apoptosis-provoking effect by utilizing cell viability 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, fluorescence microscope, gene overexpression, Western blot, and flow cytometry analyses. Parecoxib enhanced the ability of resveratrol to inhibit cell viability and increase apoptosis. Parecoxib in combination with resveratrol strongly enhanced apoptosis by inhibiting the expression of thioredoxin domain containing 5 (TXNDC5) and Akt phosphorylation. Parecoxib enhanced resveratrol-provoked c-Jun N-terminal kinase (JNK) and p38 phosphorylation. Overexpression of TXNDC5 and repression of JNK and p38 pathways significantly reversed the inhibition of cell viability and stimulation of apoptosis by the parecoxib/resveratrol combination. This study presents evidence that parecoxib enhances the anti-cancer power of resveratrol in DLD-1 colorectal cancer cells via the inhibition of TXNDC5 and Akt signaling and enhancement of JNK/p38 MAPK pathways. Parecoxib may be provided as an efficient drug to sensitize colorectal cancer by resveratrol.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anesthesiology, Chang Gung Memorial Hospital at Chiayi, No. 8, West Section of Jiapu Road, Chiayi County, Puzi City 613016, Taiwan.
- Department and Graduate Institute of Pharmacology, College of Medicine, National Taiwan University, No. 1, Jen Ai Road Section 1, Taipei 100233, Taiwan.
- School of Health Science, Division of Applied Biomedical Science and Biotechnology, IMU University, Bukit Jalil, Kuala Lumpur 57000, Malaysia.
- Institute of Medicine, Chung Shan Medical University, No. 110, Section 1, Jianguo North Road, Taichung City 402306, Taiwan.
- Department of Microbiology, Immunology and Biopharmaceuticals, College of Life Sciences, National Chiayi University, A25-303 Room, Life Sciences Hall, No. 300, Syuefu Road, Chiayi City 600355, Taiwan.
ORCID-Profile: Kai-Chien Yang, Ching-Hsein Chen
Förderung
- Chiayi Chang Gung Memorial Hospital
- Chang Gung Medical Foundation
Zitieren
APA
Chang, W. L., Yang, K. C., Peng, J. Y., Hong, C. L., Li, P. C., Chye, S. M., Lu, F. J., Shih, C. W., & Chen, C. H. (2024). Parecoxib Enhances Resveratrol against Human Colorectal Cancer Cells through Akt and TXNDC5 Inhibition and MAPK Regulation. Nutrients. https://doi.org/10.3390/nu16173020
Vancouver
Chang WL, Yang KC, Peng JY, Hong CL, Li PC, Chye SM, et al. Parecoxib Enhances Resveratrol against Human Colorectal Cancer Cells through Akt and TXNDC5 Inhibition and MAPK Regulation. Nutrients. 2024. doi:10.3390/nu16173020
BibTeX
@article{Chang2024,
author = {Chang, Wan-Ling and Yang, Kai-Chien and Peng, Jyun-Yu and Hong, Chain-Lang and Li, Pei-Ching and Chye, Soi Moi and Lu, Fung-Jou and Shih, Ching-Wei and Chen, Ching-Hsein},
title = {Parecoxib Enhances Resveratrol against Human Colorectal Cancer Cells through Akt and TXNDC5 Inhibition and MAPK Regulation},
journal = {Nutrients},
year = {2024},
doi = {10.3390/nu16173020}
}
EUVIMED